1219741-21-5

Basic information

• Product Name: 5-chloro-6-iodo-2,3-dihydro-1H-1,3-benzodiazole-2-thione
• Synonyms: 5-chloro-6-iodo-2,3-dihydro-1H-1,3-benzodiazole-2-thione;5-Chloro-6-iodo-1H-benzo[d]imidazole-2(3H)-thione
• CAS NO: 1219741-21-5
• Molecular Formula: C₇H₄ClIN₂S
• Molecular Weight: 310.54253
• EINECS: -0
• Mol File: 1219741-21-5.mol

Chemical Properties

• Boiling Point: 374.9±52.0 °C(Predicted)
• Appearance: /
• Density: 2.23±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.14±0.30(Predicted)
• CAS DataBase Reference: 5-chloro-6-iodo-2,3-dihydro-1H-1,3-benzodiazole-2-thione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-6-iodo-2,3-dihydro-1H-1,3-benzodiazole-2-thione(1219741-21-5)
• EPA Substance Registry System: 5-chloro-6-iodo-2,3-dihydro-1H-1,3-benzodiazole-2-thione(1219741-21-5)

Safety Data

• Hazardous Substances Data: 1219741-21-5(Hazardous Substances Data)

Upstream product

• 1219741-20-4 2, 4-chloro-5-iodobenzene-1,2-diamine 
• 75-15-0 carbon disulfide 
• 335349-57-0 2-nitro-4-iodo-5-chloroaniline 
• 1635-61-6 5-chloro-2-nitroaniline 

Downstream Products

• 1219741-22-6 6-chloro-5-iodo-2-(methylthio)-1H-benzimidazole 
• 1473415-09-6 6-chloro-5-(4-chlorophenyl)-2-trifluoromethylthiobenzimidazole 
• 1473415-10-9 6-chloro-5-(3-chlorophenyl)-2-trifluoromethylthiobenzimidazole 
• 1219741-57-7 methyl 5-[(5-biphenyl-4-yl-6-chloro-1H-benzimidazol-2-yl)oxy]-2-methylbenzoate 
• 1219741-19-1 6-chloro-5-iodo-2-(methylsulfonyl)-1H-benzo[d]imidazole 
• 1219737-12-8 5-((5-([1,1'-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid 
• 1219739-36-2 5-((6-chloro-5-(1-methyl-1H-indol-5-yl)-1H-benzo[d]-imidazol-2-yl)oxy)-2-methylbenzoic acid 
• 1332706-74-7 1-({[5-(biphenyl-4-yl)-6-chloro-1H-benzimidazol-2yl]oxy}methyl)cyclopropane carboxylic acid 
• 1332707-02-4 methyl 1-({[5-(biphenyl-4-yl)-6-chloro-1-(prop-2-en-1-yl)-1H-benzimidazol-2-yl]oxy}methyl)cyclopropanecarboxylate 
• 1332706-65-6 3-{[5-(biphenyl-4-yl)-6-chloro-1H-benzimidazol-2yl]oxy}cyclobutanecarboxylic acid 
• 1332706-96-3 ethyl 3-{[5-(biphenyl-4-yl)-6-chloro-1-{[2-(trimethylsilyl)ethoxy]-methyl}-1H-benzimidazol-2-yl]oxy}cyclobutanecarboxylate 
• 1332706-64-5 3-{[5-(biphenyl-4-yl)-6-chloro-1H-benzimidazol-2-yl]oxy}cyclopentane carboxylic acid 
• 1332706-95-2 ethyl 3-{[5-(biphenyl-4-yl)-6-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazol-2-yl]oxy}cyclopentanecarboxylate 
• 1332706-63-4 3-{[5-(biphenyl-4-yl)-6-chloro-1H-benzimidazol-2-yl]oxy}cyclohexanecarboxylic acid 

Relevant articles and documents

Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase

5′-Adenosine monophosphate-activated protein kinase (AMPK) is a key regulator of mammalian energy homeostasis and has been implicated in mediating many of the beneficial effects of exercise and weight loss including lipid and glucose trafficking. As such,

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1′-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase

AMP-activated protein kinase (AMPK) plays an essential role as a cellular energy sensor and master regulator of metabolism in eukaryotes. Dysregulated lipid and carbohydrate metabolism resulting from insulin resistance leads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM). While pharmacological activation of AMPK is anticipated to improve these parameters, the discovery of selective, direct activators has proven challenging. We now describe a hit-to-lead effort resulting in the discovery of a potent and selective class of benzimidazole-based direct AMPK activators, exemplified by 5-((5-([1,1′-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid, 42 (MK-3903). Compound 42 exhibited robust target engagement in mouse liver following oral dosing, leading to improved lipid metabolism and insulin sensitization in mice.

PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF

The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK- activated protein kinase. The compounds of the present invention are useful in

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK- activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.